AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $35.11.

A number of research analysts have recently weighed in on the company. HC Wainwright reiterated a “neutral” rating and set a $22.00 price target on shares of AnaptysBio in a report on Tuesday, March 4th. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a report on Monday, March 3rd. Truist Financial reduced their price target on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company increased their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 65,184 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the acquisition, the director now directly owns 7,860,180 shares of the company’s stock, valued at approximately $101,553,525.60. This represents a 0.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 33.70% of the stock is owned by company insiders.

Institutional Trading of AnaptysBio

A number of institutional investors have recently bought and sold shares of the business. Fairmount Funds Management LLC bought a new stake in shares of AnaptysBio in the 4th quarter valued at about $24,050,000. Boxer Capital Management LLC acquired a new position in AnaptysBio during the fourth quarter valued at approximately $17,212,000. Sanofi bought a new stake in AnaptysBio in the fourth quarter valued at approximately $10,882,000. FMR LLC raised its holdings in AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after purchasing an additional 438,557 shares during the period. Finally, Soleus Capital Management L.P. bought a new position in shares of AnaptysBio during the fourth quarter worth $5,481,000.

AnaptysBio Price Performance

Shares of ANAB opened at $17.08 on Friday. The company has a 50-day moving average of $16.80 and a two-hundred day moving average of $22.67. The stock has a market cap of $523.79 million, a price-to-earnings ratio of -2.81 and a beta of 0.02. AnaptysBio has a one year low of $12.21 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $43.11 million during the quarter, compared to analyst estimates of $10.17 million. Analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.